H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical (DERM) with a Buy rating and $13 price target The firm believes the company’s Emrosi has demonstrated clinical superiority to market leader Oracea in rosacea. This creates the potential for prescription demand and revenue pull through to exceed current consensus expectations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: